These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34943337)

  • 1. Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma-A Romanian Perspective.
    Berghea EC; Balgradean M; Pavelescu C; Cirstoveanu CG; Toma CL; Ionescu MD; Bumbacea RS
    Children (Basel); 2021 Dec; 8(12):. PubMed ID: 34943337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
    Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
    Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience.
    Licari A; Castagnoli R; Denicolò C; Rossini L; Seminara M; Sacchi L; Testa G; De Amici M; Marseglia GL;
    Curr Respir Med Rev; 2017 Mar; 13(1):36-42. PubMed ID: 29213221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab: a review of its use in the management of allergic asthma.
    Bang LM; Plosker GL
    Treat Respir Med; 2004; 3(3):183-99. PubMed ID: 15219177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on omalizumab in allergic asthma.
    Bang LM; Plosker GL
    BioDrugs; 2004; 18(6):415-8. PubMed ID: 15571425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab: a review of its use in the treatment of allergic asthma.
    Plosker GL; Keam SJ
    BioDrugs; 2008; 22(3):189-204. PubMed ID: 18481901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
    Dewilde S; Turk F; Tambour M; Sandström T
    Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
    J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab: a review of its use in patients with severe persistent allergic asthma.
    McKeage K
    Drugs; 2013 Jul; 73(11):1197-212. PubMed ID: 23812924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety Studies of Omalizumab in Children and Adolescents With Moderate-To-Severe Asthma.
    Cheng L; Yang T; Ma X; Han Y; Wang Y
    J Pharm Pract; 2023 Apr; 36(2):370-382. PubMed ID: 34384308
    [No Abstract]   [Full Text] [Related]  

  • 14. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-IgE antibodies for the treatment of asthma.
    Buhl R
    Curr Opin Pulm Med; 2005 Jan; 11(1):27-34. PubMed ID: 15591885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical efficacy of omalizumab for treatment of moderate or severe allergic asthma in children with serum immunoglobulin E levels >1 500 IU/mL: a prospective study].
    Luo MX; Hua S; Wei W
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Sept 15; 25(9):959-965. PubMed ID: 37718403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study.
    Schreiber J; Schwab Sauerbeck I; Mailänder C
    Adv Ther; 2020 Jan; 37(1):353-363. PubMed ID: 31741282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).
    D'Amato G; Bucchioni E; Oldani V; Canonica W
    Treat Respir Med; 2006; 5(6):393-8. PubMed ID: 17154668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab in the management of patients with allergic (IgE-mediated) asthma.
    Sandström T
    J Asthma Allergy; 2009 May; 2():49-62. PubMed ID: 21437144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.